# A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

> **NCT03573960** · PHASE4 · COMPLETED · sponsor: **Eisai Pharmaceuticals India Pvt. Ltd** · enrollment: 50 (actual)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT03573960
- **Lead sponsor:** Eisai Pharmaceuticals India Pvt. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-01
- **Primary completion:** 2025-09-04
- **Final completion:** 2025-09-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573960, "A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03573960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*